Company intelligence / Profile preview

IDECC

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

IDEC Pharmaceuticals was a pioneering biotechnology company primarily focused on the development of monoclonal antibody-based therapies for oncology and autoimmune diseases. The company is best known for co-developing Rituxan (rituximab), the first monoclonal antibody approved by the FDA for the treatment of cancer, specifically non-Hodgkin lymphoma. IDEC also developed Zevalin, the first radioimmunotherapy approved for cancer treatment. In 2003, IDEC Pharmaceuticals merged with Biogen to form Biogen Idec, which later rebranded back to Biogen, where its legacy products continue to be major therapeutic staples.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyRadiopharmaceutical
Industry: Biotech

Partnerships

GenentechRocheSchering AG

Beyond the preview

Go deeper on IDECC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDECC.

Explore the full profile